HomeSRPT • NASDAQ
Sarepta Therapeutics Inc
$99.20
0.84%
+0.83 Today
Mar 14, 12:08:03 PM UTC-4 · USD · NASDAQ · Disclaimer
Financials
Income Statement
0200M400M600M
Revenue
Net Income
Revenue
Net income
(USD)Dec 2024Y/Y change
Revenue
658.41M65.94%
Operating expense
164.47M24.17%
Net income
159.05M248.37%
Net profit margin
24.16109.90%
Earnings per share
1.90131.71%
EBITDA
172.14M378.20%
Effective tax rate
7.39%—
01B2B3B
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Dec 2024Y/Y change
Cash and short-term investments
1.35B-19.18%
Total assets
3.96B21.40%
Total liabilities
2.44B1.26%
Total equity
1.53B—
Shares outstanding
97.03M—
Price to book
6.24—
Return on assets
10.69%—
Return on capital
14.68%—
0500M
Net Change in Cash
Net change in cash
(USD)Dec 2024Y/Y change
Net income
159.05M248.37%
Cash from operations
92.05M268.41%
Cash from investing
764.12M1,287.29%
Cash from financing
48.99M2,421.41%
Net change in cash
905.16M873.16%
Free cash flow
16.42M181.63%
StockUS listed security
Previous close
$98.37
Day range
$98.63 - $100.00
Year range
$97.11 - $173.25
Market cap
9.53B USD
Avg Volume
951.61K
P/E ratio
42.42
Dividend yield
-
Primary exchange
NASDAQ
About
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
Founded
1980
Employees
1,372
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Main menu
Google apps